Allen & Overy (A&O) and Clifford Chance (CC) have scored the leading roles on GlaxoSmithKline’s (GSK’s) £1.35bn sale of its Ribena and Lucozade brands to Japan’s Suntory Beverage & Food.
The UK healthcare company has sold off the well-known drink brands after a strategic review which began in February this year. Ribena and Lucozade, which date back to 1927 and 1937 respectively, brought in around £500m for GSK last year in annual sales.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]